Figure 3.

Anti-SARS-CoV-2 activity of safe-in man broad-spectrum antivirals in Vero-E6 cells. (a) Structure-antiviral activity relation of 136 broad-spectrum antivirals (BSAAs). The compounds were clustered based on their structural similarity calculated by ECPF4 fingerprints and visualized using the D3 JavaScript library. The anti-SARS-CoV-2 activity of the compounds was quantified using the AUC and shown as bubbles. Bubble size corresponds to compounds AUCs. (b) Vero-E6 cells were treated with increasing concentrations of a compound and infected with the HCoV-19/Norway/Trondheim-E9/2020 strain (moi, 0.1) or mock. After 72 h, the viability of the cells was determined using the CellTiter-Glo assay. Mean ± SD; n = 3. (c) Table showing half-maximal cytotoxic concentration (CC₅₀), the half-maximal effective concentration (EC₅₀) and selectivity indexes (SI = CC₅₀/EC₅₀) for selected anti-SARS-CoV-2 compounds calculated from CTG and plaque assays. Mean ± SD; n = 3.